(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
21 March 2013 (21.03.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/039859 A1

(51) International Patent Classification:
A61K 38/17 (2006.01) *C07K 14/435* (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:
PCT/US2012/054567

(22) International Filing Date:
11 September 2012 (11.09.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/533,545 12 September 2011 (12.09.2011) US

(72) Inventor; and
(71) Applicant : **GRAY, Lloyd S.** [US/US]; c/o Tau Therapeutics, LLC, 600 East Water Street, Suite E, Charlottesville, Virginia 22902 (US).

(74) Agent: **GROLZ, Edward W.**; Scully, Scott, Murphy & Presser, 400 Garden City Plaza, Suite 300, Garden City, NY 11530 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

WO 2013/039859 A1

(54) Title: ANTAGONISTS OF PRODUCTS OF THE HS.459642 UNIGENE CLUSTER FOR THE INHIBITION OF PROLIFERATION, DEVELOPMENT OR DIFFERENTIATION OF STEM CELLS INCLUDING CANCER STEM CELLS

(57) Abstract: The present disclosure provides methods and compositions for inhibiting the proliferation, differentiation, or development of stem cells and cancer stem cells in a patient in need thereof. The methods involve administering to a patient a therapeutically effective amount of an antagonist of an Hs.459642 Unigene Cluster product, such as an inhibitor of CACNA1H. The compositions include an antagonist of an Hs.459642 Unigene Cluster product, such as an inhibitor of CACNA1H. Specific antagonists such as antibodies and antisense oligonucleotides, and combination therapy with one or more additional anti-cancer agents, are also provided by this disclosure. Such methods, antagonists, and compositions can be useful, for example, in the treatment of cancer.